Immunoregulation is a highly evolved biologic response able to finetune inflammation and innate immunity but also able to modulate adaptive immunity and establish tolerance to self 1,2 . Catabolism of amino acids is an ancient survival strategy that can additionally control immune responses in mammals 3 . Several metabolic enzymes are known to have a second function, which allows them to meet additional functional challenges and needs in the cell 4 . Three distinct enzymes, tryptophan 2,3-dioxygenase (confined to the liver), indoleamine 2,3-dioxygenase (IDO; IDO1) and the IDO paralog indoleamine 2,3-dioxygenase-2 (IDO2), catalyze the same ratelimiting step of tryptophan catabolism along a common pathway, which leads to tryptophan starvation and the production of tryptophan metabolites collectively known as kynurenines [5] [6] [7] . However, IDO alone is recognized as an authentic regulator of immunity in a variety of pathophysiological conditions, including pregnancy, infection, allergy, autoimmunity, chronic inflammation, transplantation and mechanisms for the escape of tumors from the immune system 8, 9 .
Immunoregulation is a highly evolved biologic response able to finetune inflammation and innate immunity but also able to modulate adaptive immunity and establish tolerance to self 1, 2 . Catabolism of amino acids is an ancient survival strategy that can additionally control immune responses in mammals 3 . Several metabolic enzymes are known to have a second function, which allows them to meet additional functional challenges and needs in the cell 4 . Three distinct enzymes, tryptophan 2,3-dioxygenase (confined to the liver), indoleamine 2,3-dioxygenase (IDO; IDO1) and the IDO paralog indoleamine 2,3-dioxygenase-2 (IDO2), catalyze the same ratelimiting step of tryptophan catabolism along a common pathway, which leads to tryptophan starvation and the production of tryptophan metabolites collectively known as kynurenines [5] [6] [7] . However, IDO alone is recognized as an authentic regulator of immunity in a variety of pathophysiological conditions, including pregnancy, infection, allergy, autoimmunity, chronic inflammation, transplantation and mechanisms for the escape of tumors from the immune system 8, 9 .
IDO normally has low basal expression but is rapidly induced by interferon-γ (IFN-γ) in dendritic cells (DCs) [8] [9] [10] . The IFN-γ-IDO axis is considered to be a phylogenetically conserved mechanism for restricting microbial growth and avoiding potentially harmful hyperinflammatory responses in the host 11 . However, its regulatory function in pregnancy and the long-term prevention of immunopathology has remained unclear [8] [9] [10] . Autocrine or paracrine signaling through transforming growth factor-β (TGF-β) can also induce long-term, IDO-dependent effects 12 . The TGF-β-IDO axis has been shown to mediate durable regulatory functions, with a chief role in the generation and maintenance of regulatory T cells 13 .
Functional flexibility and the fostering of regulatory T cell responses are features typical of CD11c lo B220 hi plasmacytoid DCs (pDCs), which can activate but also suppress both inflammatory or innate responses and adaptive immunity [14] [15] [16] [17] . Although different forms of immunosuppressive mechanisms are exploited by pDCs in distinct environmental conditions 15 , IDO is one of the key molecular components responsible for pDC-induced tolerogenesis 9, 18 . Thus, depending on the specific pathophysiological context, IDO and pDCs show adaptable and integrated modes of immune control. Here we provide evidence that IDO expressed by pDCs met different environmental needs, and in particular, that locally produced cytokines changed its main function from an intense but short course of tryptophan degradation (as in IFN-γ-dominated innate or inflammatory responses) to a TGF-β-driven, self-maintaining form of intracellular signaling activity that, independently of tryptophan degradation, contributed to sustaining a stably regulatory phenotype in pDCs, as required by tolerance mechanisms.
RESULTS

IDO regulatory functions independent of its catalytic activity
We compared the effects of conditioning pDCs with either IFN-γ or TGF-β in cocultures established with naive CD4 + CD25 − T lymphocytes. To identify IDO-dependent effects of either cytokine, we transfected groups of pDCs with small interfering RNA (siRNA) targeting Ido1 or Ido2 (Supplementary Fig. 1 ) or treated them with 1-methyltryptophan (1-MT), an inhibitor of the enzymic activity of IDO, before conditioning the cells with cytokines. We assessed proliferation, apoptosis and the frequency of cells expressing the coreceptor CD4 and the regulatory T cell-specific transcription factor Foxp3, as well as the cytokine profile, after 1-4 d of culture. Pretreatment of pDCs with IFN-γ induced less CD4 + cell proliferation ( Fig. 1a and Supplementary Fig. 2 ) and a greater rate of CD4 + cell apoptosis ( Fig. 1b and Supplementary Fig. 3 ) than that in cocultures established with untreated pDCs, but pretreatment with TGF-β did not. In contrast, pretreatment of pDCs with TGF-β induced a greater frequency of Foxp3 + cells in the CD4 + cell population ( Fig. 1c and Supplementary Fig. 4) , which was also characterized by considerable suppressive activity in vitro (Fig. 1d) . Supernatants from cocultures established with TGF-β contained more interleukin 27 (IL-27) but less IL-6 than did control cocultures with untreated pDCs, but supernatants from those established with IFN-γ-treated pDCs did not (Fig. 1e) . However, although we did find secreted cytokines in culture supernatants, TGF-β was present in a large latent complex or as a biologically active cell surface molecule 13 , as demonstrated by cellular staining for the cytokine (Fig. 1f) and real-time PCR analysis (Supplementary Fig. 5 ). Stimulation with TGF-β also induced TGF-β expression in pDCs from wild-type mice but not those from IDO-deficient (Ido1 −/− ) mice ( Fig. 1f and Supplementary Fig. 5 ). Although silencing of Ido1 abrogated the in vitro effects of both IFN-γ and TGF-β (but silencing of Ido2 did not), the use of 1-MT prevented the IFN-γ-dependent but not the TGF-β-mediated immunomodulatory effect on the pDCs (Fig. 1a-e) . Therefore, TGF-β induces TGF-β-and IDO-dependent regulatory functions in pDCs in vitro that do not require the catalyst function of IDO.
TGF-b induces regulatory functions of IDO in pDCs in vivo
In in vivo experiments, we sensitized female mice with the H-2D brestricted HY peptide (containing the immunodominant epitope of the male mouse-specific minor transplantation antigen) presented by CD11c hi conventional DCs administered alone or in combination with a minority fraction of potentially regulatory pDCs that had been left untreated or pretreated with IFN-γ or TGF-β. After priming the mice, we assessed reactivity at 2 weeks by intrafootpad challenge with HY peptide in the absence of DCs, according to an established protocol for measuring the induction of immunoreactivity versus tolerance 19, 20 . The priming ability of conventional DCs was not affected by the presence of untreated pDCs 20 , yet sensitization together with pDCs pretreated with either cytokine caused suppression of HY-specific reactivity, an effect abrogated by silencing of Ido1 but not by silencing of Ido2 in the pDCs used for sensitizing hosts. However, 1-MT selectively blocked the immunosuppressive effect induced by pretreatment of pDCs with IFN-γ but not by pretreatment with TGF-β, and the immunosuppressive effect of pDCs was abolished by neutralization of endogenous TGF-β (Fig. 2a) . We observed a conspicuous lymphomononuclear infiltrate in the peptidechallenged footpads of mice with detectable reactivity to the skin test (Fig. 2b) , whose popliteal lymph nodes expressed a T helper type 1-type response dominated by the production of IFN-γ (Fig. 2c) . We observed significantly more Foxp3-expressing CD4 + cells in the popliteal lymph nodes but not the spleens or mesenteric lymph nodes of mice with a negative skin test that were selectively treated with TGF-β-conditioned pDCs ( Fig. 2d and Supplementary Figs. 6  and 7) . These data suggest that TGF-β induces IDO-dependent immunoregulatory effects in pDCs in vivo that are distinct in nature from those induced by IFN-γ and are independent of the catalyst function of IDO.
TGF-b activates tyrosine phosphatases in pDCs
Immunoreceptor tyrosine-based inhibitory motifs (ITIMs) are known to signal through the recruitment and activation of the tyrosine phosphatases SHP-1 and SHP-2 and the inositol polyphosphate phosphatase SHIP 21, 22 . A prototypic ITIM has the sequence I/V/L/ SXYXXL/V/F (where 'I/V/L/S' indicates isoleucine, valine, leucine or serine; 'X' indicates any amino acid; 'Y' is the tyrosine that can be phosphorylated; and 'L/V/F' indicates leucine, valine or phenylalanine) 23, 24 . In the presence of inflammatory stimuli, phosphorylated 
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ITIMs bind ubiquitin-recruiting molecule SOCS3, which mediates proteasomal degradation of ITIM-bearing molecules 25, 26 . Mouse IDO has two putative ITIMs that, in the presence of proinflammatory IL-6, are involved in SOCS3-dependent proteasomal degradation of the enzyme 27 . Alignment of human, dog, rat and mouse IDO proteins indicated that the putative ITIMs in mouse IDO (called 'ITIM1' and 'ITIM2' here) are well conserved in mammals and are located at sites distant from the catalytic domain. In contrast, in mouse and human IDO2, as well as in their chicken and fish counterparts, only the putative ITIM2 is present because of a substitution of tyrosine with phenylalanine in ITIM1.
To investigate whether IDO has ITIM-mediated signaling ability, we first evaluated the kinetics of the phosphorylation of the ITIM in IDO as well as the expression of SHP-1, SHP-2 and SHIP in pDCs treated with TGF-β or IFN-γ. Using an antibody to a peptide containing the tyrosine-phosphorylated form of IDO ITIM2 (Supplementary Fig. 8 ), we found that as early as 30 min after treatment, TGF-β induced the appearance of molecules containing phosphorylated IDO ITIM2 in the range of the known IDO protein size (42-45 kilodaltons), but IFN-γ did not (Fig. 3a) . We found no binding of the antibody to phosphorylated IDO ITIM2 in lysates of Ido1 −/− pDCs treated with TGF-β or IFN-γ (data not shown). The expression of genes encoding SHP-1 (Ptpn6), SHP-2 (Ptpn11) and SHIP (Inpp5d) increased at 16-24 h in response to TGF-β but not in response to IFN-γ (Fig. 3b) . In contrast, treatment of pDCs with IL-6 invariably led to lower expression of these genes (data not shown).
To verify that the phosphorylated ITIMs in IDO represented true docking sites for phosphatases, we used biotinylated peptides containing phosphorylated or unphosphorylated ITIM1 or ITIM2 in IDO to precipitate SHP-1, SHP-2 and SHIP. We exposed lysates from mouse P1 tumor cells (which have constitutively high expression of phosphatases) and pDCs (incubated for 24 h with TGF-β) to the biotinylated peptides and immunoprecipitated proteins from the lysates with streptavidin-agarose (Fig. 3c) . SHIP binding was not detectable under any conditions. In contrast, SHP-1 and SHP-2 bound phosphorylated ITIM1 and phosphorylated ITIM2 but not their unphosphorylated counterparts in both cell types.
In coimmunoprecipitation experiments, SHP-1 and SHP-2 were barely detectable in IDO immunoprecipitates obtained from lysates of pDCs in the absence of cytokine treatment (Fig. 3d) . However, the efficiency of coimmunoprecipitation of SHP-1 and SHP-2 was greater in lysates of pDCs treated with TGF-β for 24 h. In addition, we found substantial tyrosine-phosphatase activity in IDO coimmunoprecipitates from pDCs treated with TGF-β, but those effects were markedly suppressed by transfection of pDC with siRNA targeting Ptpn6 or Ptpn11 or by treatment with stibogluconate (a specific SHP-1 inhibitor) before treatment with TGF-β ( Fig. 3e and Supplementary Fig. 9 ).
We next assessed the ratio of bound IDO to total IDO in IDOtransfected pDCs, which, unlike unmanipulated cells, can provide sufficient amounts of coimmunoprecipitate. We calculated the amount of bound IDO as the difference between total IDO and residual IDO after immunoprecipitation with antibody to SHP (anti-SHP). We determined the amount of IDO in whole-cell lysates by immunoblot analysis with anti-IDO before immunoprecipitation (total amount) and after immunoprecipitation (residual amount). In two independent experiments, the reduction in ratios of IDO to β-tubulin in TGF-β-treated pDCs after coimmunoprecipitation with anti-SHP-1 or anti-SHP-2 was 23.8% or 23.2%, respectively (data not shown). Therefore, approximately one-fourth of total IDO seemed to have immunoprecipitated together with SHP-1 or SHP-2 (and thus seemed to have been phosphorylated) in pDCs treated with TGF-β. Studies of P1 cells transfected with constructs encoding IDO mutants lacking the ITIM1 tyrosine residue, the ITIM2 tyrosine residue or the histidine residue required for catalytic activity showed that both ITIMs were required for the binding and activation of tyrosine phosphatases, an ability not shared by IDO2, but the catalytic site was not required (Fig. 3f,g ). These data suggest that in pDCs, TGF-β induces phosphorylation of IDO ITIMs and upregulation of SHP-1 and SHP-2 and thus favors the formation of IDO-SHP-1-SHP-2 complexes and activation of the phosphatase activity of SHP-1 and SHP-2. 
Phosphorylation of IDO ITIMs dependent on the kinase Fyn TGF-β modulates many diverse cellular phenotypes in distinct types of cell via pathways dependent on and independent of the signal transducer Smad 13 . Smad-independent signaling includes the phosphatidylinositol-3-OH kinase (PI(3)K) pathway, which might link TGF-β with the noncanonical transcription factor NF-κB pathway 13 . We used an inhibitor of all of the downstream effects of Smad (SIS3) and a PI(3)K-specific inhibitor (LY294002) to investigate the effects of Smad-dependent and Smad-independent TGF-β-induced pathways on both the phosphorylation of IDO (Fig. 4a) and transcription of Ptpn6 (Fig. 4b) . The results showed that IDO phosphorylation (which happens early) was Smad independent but PI(3)K dependent, whereas the later induction of Ptpn6 was contingent on both Smad and PI(3)K.
We looked for the kinase responsible for phosphorylation of the critical tyrosine residues in IDO ITIMs. To gain preliminary insight, we searched the pDC gene-expression profiles in public data sets, focusing on Src kinases known to mediate surface receptor-dependent tyrosine-phosphorylation of intracellular target proteins 28 . The profile analysis indicated that among several possibilities, including Sykb, Blk, Frk, Zap70, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes1 and Csk, the most widely represented kinase in naive mouse pDCs was the product of Fyn (Fig. 4c,d) . Consistent with those data, we found very abundant expression of Fyn in pDCs, such that treatment with TGF-β resulted in only marginally higher protein expression (Fig. 4e) . To investigate any function of Fyn in TGF-β-induced phosphorylation of ITIM tyrosine residues in IDO, we pretreated pDCs with the Fyn inhibitor PP2 or the control compound PP3, or with an inhibitor of Syk, the A r t i c l e s main kinase related to the tyrosine phosphorylation of immunoreceptor tyrosine-based activation motifs or ITIMs in other cell types 29 .
Immunoblot analysis demonstrated that selective inhibition of Fyn function greatly impaired the phosphorylation of IDO (Fig. 4f ). These data demonstrate that the TGF-β-induced association of IDO ITIMs with SHP molecules requires Fyn-dependent phosphorylation of IDO, whereas induction of SHP expression is mediated through a combination of Smad-dependent and Smad-independent mechanisms.
TGF-b-IDO-SHP axis activates the noncanonical NF-kB pathway
We sought to gain insight into the signaling circuitry and the downstream targets activated by the TGF-β-IDO-SHP axis in pDCs. In splenocytes, SHP-1 inhibits the kinase IRAK1 and tips the balance of activation of canonical versus noncanonical NF-κB pathway in favor of the latter, resulting in upregulated production of type I interferon 30, 31 . We evaluated the activation of the canonical and noncanonical NF-κB pathways and the production of IFN-α and IFN-β in pDCs in response to TGF-β and IFN-γ. As reported before 12 , at 30 min, TGF-β induced phosphorylation of the kinase IKKα, which is known to be indispensable for activation of the noncanonical NF-κB pathway. There was no increase in the phosphorylation of kinase IKKβ, which is pivotal in the canonical NF-κB pathway (Fig. 5a) . In contrast, IFN-γ induced low, yet detectable, phosphorylation of both kinases. In addition, we found a selective increase in the nuclear translocation of the NF-κB subunits p52 and RelB (both functional markers of the noncanonical NF-κB pathway) in pDCs treated for 30-60 min with TGF-β, whereas IFN-γ had negligible effects (Fig. 5b) . We found significant IFN-α (Fig. 5c) and IFN-β (data not shown) in culture supernatants obtained by treatment of pDCs for 24 h with TGF-β, but not after treatment with IFN-γ. Silencing of either Ptpn6 or Ptpn11 markedly impaired the nuclear translocation of p52 (Fig. 5b) and production of IFN-α (Fig. 5c ) in TGF-β-treated pDCs. In addition, silencing of both Ptpn6 and Ptpn11 or of Ido1 or of the gene encoding IKKα (Chuk) 20 abrogated the production of IFN-α (Fig. 5c) and IFN-β (data not shown) in TGF-β-treated pDCs. We obtained no such effect by silencing Ido2 or Ikbkb (which encodes IKKβ) or by treating cells with 1-MT (Fig. 5c) . Silencing of Irak1 resulted in considerable upregulation of IFN-α production in pDCs treated for 24 h with TGF-β (Fig. 5c) , consistent with the reported inhibitory effect of IRAK1 on the release of type I interferon 30 . In coimmunoprecipitation experiments, the basal association of IRAK1 with SHP proteins was enhanced by TGF-β (Fig. 5d) . Thus, SHP-1 favors TGF-β-dependent activation of the noncanonical NF-κB pathway and IFN-α production in pDCs via pathways involving IRAK1.
IDO phosphorylation initiates a circuit of downstream events
Next we used wild-type pDCs pretreated with siRNA targeting Ptpn6-Ptpn11, Chuk or Ikbkb or pDCs purified from Ifnar −/− mice (which lack the gene encoding the receptor for IFN-α-IFN-β) to investigate the role of IDO-dependent pathways in TGF-β signaling. In pDC-T cell cocultures, lack of Ptpn6-Ptpn11, Chuk or Ifnar in pDCs greatly impaired the ability of TGF-β-treated pDCs to induce CD4 + Foxp3 + cells ( Fig. 6a and Supplementary Fig. 10 ) and diminished IL-6 production (Fig. 6b) , but lack of Ikbkb did not. Lack of Ptpn6-Ptpn11 or Chuk also blocked the expression of TGF-β transcripts in isolated pDCs (Fig. 6c) and abrogated the immunosuppressive ability of TGF-β-conditioned pDCs in an in vivo experimental setting of skin reactivity to the peptide IGRP (containing the prevalent diabetogenic H-2K d -restricted epitope of the islet-specific glucose-6-phosphatase catalytic subunit-related protein), but lack of Ikbkb did not (Fig. 6d) . We also observed a similar loss of immunosuppressive activity of TGF-β-conditioned pDCs in Ifnar −/− mice or after treatment of pDCs with the Fyn inhibitor PP2 (but not after treatment with the negative control PP3) before the addition of TGF-β (Fig. 6d) . In contrast, loss of these genes had no detectable effect on the IFN-γ-driven pDC function (Supplementary Fig. 11) . Analysis of the promoter of the gene encoding mouse TGF-β (Tgfb1) has shown that the region contains four noncanonical NF-κB-binding sites located at positions −1437, −1319, −1162 and −743 relative to the start site for Tgfb1 transcription. Although direct interaction of these promoters with activator proteins has not been formally proven yet, the finding of those binding sites suggests that NF-κB family members regulate the induction of TGF-β at a transcriptional level. Overall, the data indicate that Fyn-dependent phosphorylation of IDO recruits a variety of downstream signaling effectors, including SHP proteins and the noncanonical NF-κB pathway, that result in sustained TGF-β production, induction of type I interferons and a regulatory pDC phenotype. 
IDO induces its own expression
P t p n 6 -P t p n 1 1 P t p n 6 -P t p n 1 1 (Fig. 7a) . Chromatin-immunoprecipitation experiments showed specific binding of p52-RelB dimers and IRF8 to the Ido1 promoter in pDCs treated with TGF-β, which peaked at 3 h and 16 h, respectively (Fig. 7a) .
In pDCs transfected with a plasmid construct containing the mouse Ido1 promoter upstream of the luciferase gene, IFN-γ induced Ido1 promoter activity in an intense and rapid (at 3 h), albeit transient, way (expression returned to basal amounts at 16 h; Fig. 7b ), as reported before 33 . In response to TGF-β, however, the Ido1 promoter began to be transcriptionally active at 16 h, with considerable activity even at 48 h (Fig. 7b) . The 24-hour effect of TGF-β was completely lost in pDCs pretreated with siRNA targeting Ido1, Ptpn6-Ptpn11, Chuk or Icsbp1 (which encodes IRF8) 33 or lacking expression of Ido1 or Ifnar, whereas no ablating effect was demonstrated by the use of siRNA targeting Ido2 or Ikbkb or 1-MT (Fig. 7c) . We also found maintenance of IDO protein expression (Fig. 7d) and enzyme activity (Fig. 7e) over a longer period (up to 48 h) in pDCs pretreated with TGF-β, in contrast to those pretreated with IFN-γ; however, pretreatment with IFN-γ resulted in more IDO protein expression and activity but only at early time points (24 h). Moreover, the effects of TGF-β but not those of IFN-γ at 24 h remained measurable after removal of the cytokine by washing the cells and incubating them for an additional 24 h in medium alone (Fig. 7d,e) . These data suggest that IDO-dependent signaling results in sustained Ido1 expression in pDCs. pDCs: Ido1 A r t i c l e s
TGF-b conditioning induces long-term tolerance in vivo
To clearly discriminate the effects of IFN-γ (acute) versus TGF-β (long-term) on IDO regulation, we assessed skin-test reactivity using pDCs conditioned with either cytokine at late time points. The immunosuppressive effects of pretreatment with TGF-β were still detectable in pDCs at 1 month (data not shown) and 3 months (Fig. 8a) , but the effects of IFN-γ were not. Histological examination showed that in recipients of TGF-β-conditioned pDCs, the local inflammatory reaction was very limited (data not shown). In these mice, CD4 + Foxp3 + cells were present in the popliteal lymph nodes draining the peptide-injected footpads ( Fig. 8b and Supplementary  Fig. 12) , and unfractionated CD4 + cells failed to produce IFN-γ when restimulated in vitro with specific antigen (Fig. 8c) . In vitro, TGF-β-conditioned pDCs and CD4 + T cells cultured together in the presence or in the absence of anti-TGF-β showed that the emergence of CD4 + Foxp3 + T cells depended on TGF-β, whereas maintenance of this regulatory population did not (Fig. 8d) . Late addition (at 48 h) of anti-TGF-β did not reverse Foxp3 expression (Fig. 8d and data not shown), which indicated that once induced, the regulatory population was not absolutely contingent on TGF-β. Therefore, under the appropriate environmental conditions, IDO can activate a long-term immunoregulatory circuitry involving control of its own expression, either directly or via modulatory cytokines including TGF-β and type I interferons 34 .
DISCUSSION
Initially identified as a counter-regulatory mechanism in acute inflammation 35 and for its role in fetal-maternal tolerance 36 , tryptophan catabolism is also critical in balancing inflammation with tolerance in autoimmunity, transplantation and cancer 8, 9 . Whereas acute responses are best controlled by the IFN-γ-IDO axis 37, 38 , TGF-β is critical in establishing a regulatory phenotype in pDCs. This enables those cells to generate and sustain the function of regulatory T cells through the combined effects of tryptophan starvation and kynurenines acting via the aryl hydrocarbon receptor of T cells 13, 39, 40 . The resolution of the crystal structure of human IDO has shown its folding into a catalytic large carboxy-terminal domain, a noncatalytic small amino-terminal domain, and a long loop connecting the two domains. Beyond covering the top of the heme-binding site, the role of the noncatalytic small domain has remained unclear. By mapping the structure of human IDO (data not shown), we found that the putative ITIM1 and ITIM2 motifs corresponding to mouse IDO, although they span very distant portions of the IDO sequence, are positioned very close to each other in an exposed surface region of the protein.
In particular, ITIM1 and ITIM2 are positioned in the small domain and in the interconnecting loop, respectively. Alignment of human, dog, rat and mouse IDO proteins indicated that ITIM1 and ITIM2 sequences are well conserved in those mammals. Evolution has produced a considerable variety of adaptations in protein function, but there are some general principles, among which is the recruitment of proteins with existing functions for new purposes. The stability of proteins depends on the presence of particular motifs that make them the target of degradative or protective processes. These regulatory signals usually consist of short simple sequence patterns, including evolutionarily conserved ITIMs 41 , and new phenotypes can be generated through the use of cryptic phenotypes, as with IDO2, which contains incomplete and thus inactive ITIMs. In gene duplication, one of the two duplicate products may acquire new functions, whereas the original functions are maintained by the other. From this perspective, the ITIMs in IDO not only control the stability of the protein (via ubiquitination and proteasomal degradation driven by IL-6-induced SOCS3) 27 but also participate in a positive feedback loop operating in a self-maintaining regulatory circuitry in a TGF-β-dominated environment.
Thus, IDO not only seems to be critical in limiting potentially exaggerated inflammatory reactions in response to danger signals 11 and in assisting regulatory T cell effector function 9 but also represents an important component of a regulatory system that allows long-term control of immune homeostasis, as may be required by pregnancy 36 and tolerance to self 42 . Central to a continued homeostatic function of IDO is its ability to respond to TGF-β in the local tissue microenvironment, tip the balance of activation of the canonical versus noncanonical NF-κB pathway in favor of the latter, and modulate gene transcription to amplify itself, directly or indirectly via type I interferons, and maintain a TGF-β-dominated environment. The dual regulatory function of IDO as a catalyst and a signaling protein that uses, somewhat paradoxically, the same motifs for degradation processes, makes this enzyme one of rare functional eclecticism.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/.
pDCs (1 × 10 7 ) in Opti-MEM containing Glutamax (Invitrogen). The renilla reporter plasmid pRL-TK (1 µg; Promega) was transferred by electroporation as an internal control of the transfection process. Luciferase activity was assayed with the Dual Luciferase Reporter Assay Kit (Promega). The functional activity of IDO was measured in vitro in terms of the ability to metabolize tryptophan to l-kynurenine, whose concentration was measured by high-performance liquid chromatography in culture supernatants at various times (16-48 h) after the addition of 100 µM tryptophan for the final 8 h (refs. 11,37 ).
Statistical analysis. Student's t-test was used for analysis of the results of in vitro studies. In the in vivo skin test assay, the two-tailed paired t-test was used for statistical analysis by comparison of the mean weight of experimental footpads with that of their control, saline-injected counterparts 50 . At least six mice per group per experiment were used, as computed by power analysis to yield a power of at least 80% with an α-value of 0.05 (ref. 20) .
